z-logo
open-access-imgOpen Access
Influence of interferon-α treatment outcome in polycythemia vera and essential thrombocythemia by genetic polymorphism in IL28B
Author(s) -
Marie Lindgren,
Helna Pettersson,
Johan Westin,
Magnus Lindh,
Peter Johansson,
Björn Andréasson
Publication year - 2012
Publication title -
journal of hematological malignancies
Language(s) - English
Resource type - Journals
eISSN - 1925-4032
pISSN - 1925-4024
DOI - 10.5430/jhm.v2n3p18
Subject(s) - essential thrombocythemia , polycythemia vera , medicine , gastroenterology , genotype , genotyping , hematocrit , single nucleotide polymorphism , immunology , biology , gene , genetics

Background: Interferon-α (IFN-α) is a therapeutic option in high risk patients with Myeloproliferative Neoplasms (MPNs). The response to IFN-α treatment of chronic hepatitis C was shown to be strongly influenced by several related single nucleotide polymorphisms (SNP) in a region adjacent to the IL28B gene. The objective of this study was to investigate the possibility of similar influence of IL28B gene polymorphism in IFN-α treated MPN patients.

Methods: 20 patients with polycythemia vera (PV) or essential thrombocythemia (ET) treated with IFN-α included, 7 were earlier treated with hydroxyurea. Hematologic response was evaluated using the European Leukemia Net (ELN) criteria. DNA from whole blood samples was isolated using MagNA Pure LC DNA Isolation Kit I for IL28B genotyping, and the variability at rs12979860, rs12980275 and rs8099917 were determined by allelic discrimination assays using Taqman minor groove binding probes.

Results: The IFN-α treatment reduced platelet count (p<0.05), and in patients with polycythemia vera (PV) also hemoglobin, hematocrit and white blood cell counts declined (p<0.05). Hematologic response by ELN criteria was significantly influenced by the IL28B SNP. Among 20 patients with PV or ET, the CC genotype at rs12979860 was found in 8/11 patients (73%) with hematologic CR as compared with 1/9 (11%) with PR or NR (p=0.010).

Conclusion: The results in this pilot study indicate that variation in IL28B genotype might influence hematologic response in IFN-α treated MPN patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom